Compare Citius Pharmaceuticals Inc (CTXR) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs NEOS S&P 500 High Income ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while NEOS S&P 500 High Income ETF trades at $54.15. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SPYI | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.82 | $54.19 |
52-Week Low | $0.48 | $47.98 |
Enterprise Value | $16.23M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
